

Request for Prior Authorization Lesinurad (Zurampic)

(PLEASE PRINT – ACCURACY IS IMPORTANT)

IA Medicaid Member ID # <input style="width: 90%;" type="text"/>	Patient name <input style="width: 95%;" type="text"/>	DOB <input style="width: 95%;" type="text"/>
Patient address <input style="width: 100%;" type="text"/>		
Provider NPI <input style="width: 90%;" type="text"/>	Prescriber name <input style="width: 95%;" type="text"/>	Phone <input style="width: 95%;" type="text"/>
Prescriber address <input style="width: 95%;" type="text"/>		Fax <input style="width: 95%;" type="text"/>
Pharmacy name <input style="width: 90%;" type="text"/>	Address <input style="width: 95%;" type="text"/>	Phone <input style="width: 95%;" type="text"/>
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.		
Pharmacy NPI <input style="width: 90%;" type="text"/>	Pharmacy fax <input style="width: 95%;" type="text"/>	NDC <input style="width: 95%;" type="text"/>

Prior authorization is required for lesinurad (Zurampic). Requests for doses above the FDA approved dose will not be considered. Requests will be considered for patients when the following criteria are met:

- 1) Patient is 18 years of age or older; and
- 2) Patient has a diagnosis of hyperuricemia associated with gout; and
- 3) Patient has not achieved target serum uric acid levels or patient remains symptomatic with a maximally tolerated dose of a xanthine oxidase inhibitor (allopurinol or febuxostat) for at least 3 months; and
- 4) Patient has documentation of a previous trial and therapy failure with probenecid in combination with a xanthine oxidase inhibitor; and
- 5) Patient has an estimated creatinine clearance (eCrCl) > 45 mL/min; and
- 6) Documentation is provided lesinurad will be used in combination with a xanthine oxidase inhibitor.
 - a. If taking allopurinol, dose should be ≥ 300 mg per day (or ≥ 200 mg per day in patients with an eCrCl < 60 mL/min); and
- 7) Patient does not have a contraindication to therapy including any of the following:

a. Severe renal impairment (eCrCl <30 mL/min)	d. On dialysis
b. End stage renal disease	e. Tumor lysis syndrome
c. Kidney transplant recipient	f. Lesch-Nyhan syndrome

If criteria for coverage are met, initial requests will be given for 6 months. Continuation of therapy will be considered when the following criteria are met:

- 1) Patient continues to take medication in combination with a xanthine oxidase inhibitor.
 - a. If taking allopurinol, dose should be ≥ 300 mg per day (or ≥ 200 mg per day in patients with an eCrCl < 60 mL/min); and
- 2) Patient has an eCrCl > 45 mL/min; and
- 3) Patient does not have a contraindication to therapy including any of the following:

a. Severe renal impairment (eCrCl <30 mL/min)	d. On dialysis
b. End stage renal disease	e. Tumor lysis syndrome
c. Kidney transplant recipient	f. Lesch-Nyhan syndrome
- 4) Documentation of a positive clinical response to lesinurad.

The required trials may be overridden when documented evidence is provided that the use of the agent(s) would be medically contraindicated.

Request for Prior Authorization
Lesinurad (Zurampic) - continued
(PLEASE PRINT – ACCURACY IS IMPORTANT)

Non-Preferred

Zurampic

Strength	Dosage Instructions	Quantity	Day's Supply
_____	_____	_____	_____

Diagnosis: _____

Initial Requests:

Target Serum Uric Acid Level: _____

Current Serum Uric Acid Level (attach lab results): _____

Does patient remain symptomatic while on a maximally tolerated dose of a xanthine oxidase inhibitor for at least 3 months? Yes No

Document trial of a xanthine oxidase inhibitor:

Drug name & dose: _____ Trial dates: _____

Reason for failure: _____

Document trial of a probenecid in combination with a xanthine oxidase inhibitor:

Drug name & dose: _____ Trial dates: _____

Reason for failure: _____

Estimated Creatinine Clearance (eCrCl): _____ **Date calculated:** _____

Will lesinurad be used in combination with a xanthine oxidase inhibitor? If taking allopurinol, dose should be ≥ 300 mg per day (or ≥ 200 mg per day in patients with an eCrCl < 60 mL/min).

Yes, provide drug name and dose: _____ No

Does patient have a contraindication to therapy including any of the following:

- Severe renal impairment (eCrCl < 30 mL/min): Yes No
- End stage renal disease: Yes No
- Kidney transplant recipient: Yes No
- On dialysis: Yes No
- Tumor lysis syndrome: Yes No
- Lesch-Nyhan syndrome: Yes No

**Request for Prior Authorization
Lesinurad (Zurampic) - continued**

(PLEASE PRINT – ACCURACY IS IMPORTANT)

Renewal Requests:

Is lesinurad being used in combination with a xanthine oxidase inhibitor? If taking allopurinol, dose should be ≥ 300 mg per day (or ≥ 200 mg per day in patients with an eCrCl < 60 mL/min).

Yes, provide drug name and dose: _____ No

Estimated Creatinine Clearance (eCrCl): _____ **Date calculated:** _____

Does patient have a contraindication to therapy including any of the following:

- Severe renal impairment (eCrCl < 30 mL/min): Yes No
- End stage renal disease: Yes No
- Kidney transplant recipient: Yes No
- On dialysis: Yes No
- Tumor lysis syndrome: Yes No
- Lesch-Nyhan syndrome: Yes No

Provide documentation of positive clinical response to lesinurad therapy: _____

Attach lab results and other documentation as necessary.

Prescriber signature (Must match prescriber listed above.)	Date of submission
--	--------------------

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.